<DOC>
	<DOCNO>NCT02805452</DOCNO>
	<brief_summary>The purpose study determine whether Succinate Solifenacin reduce OverActive Bladder syndrome occur prostate irradiation .</brief_summary>
	<brief_title>Solifenacin Succinate Treatment Urinary Toxicity Occurring During Radiotherapy Prostatic Cancer</brief_title>
	<detailed_description>A multicenter Phase III , randomize , double-blinded , parallel group placebo-controlled study . 2 group : - Control arm = pt . placebo - Experimental arm = pt . Solifenacin succinate 5 mg - Vesicare® All patient OAB sub-score use USP scale great 5 prostate cancer radiotherapy include , receive either placebo Solifenacin succinate ( 5mg ) duration 3 month . The randomization stratify radiotherapy dose ( 1 40 Gy 40 70/80 Gy ) . Screening : For patient , OAB item USP scale complete standard weekly assessment prostate radiotherapy . Patients reach OAB sub-score great 5 addressed urologist order confirm absence Qmax &lt; 10ml/sec initial assessment , post-void residual urine &gt; 100 milliliter ( ml ) . Inclusion &amp; treatment : A week pre-screening , patient randomize receive either Vesicare®-5mg placebo . In study arm , treatment continue 3 month . Follow-up : The radiation oncologist perform patient ' follow-up study treatment initiation , 6 week 3 month start treatment ( Vesicare placebo ) . The questionnaire evaluation OAB syndrome , acute urinary toxicity quality life complete follow-up visit . The voiding diary complete 3 day ( , 3 day ) evaluation time . An urologist perform uroflowmetry post-voiding echography ( bladder scan ) initiation treatment , 6 week treatment . Statistics sample size PATIENTS ENROLMENT 70 patient include ( consider 66 patient complete full study ) within 3 recruitment center</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Prostate adenocarcinoma ( histological confirmation ) , Indication prostate cancer radiotherapy ( standard schema total dose 70 80 Gray ( GY ) ) , Patient affiliation French Social Security System , Patient information write informed consent , Patient complain urinary symptom radiotherapy , Occurrence OverActive Bladder ( OAB ) subscore Urinary Symptom Profile ( USP ) scale great equal 5 . Prostate irradiation contraindication History bladder prostate surgery , History pelvic radiotherapy , Individual deprive liberty place Under authority tutor , Age &lt; 18 year , Flowmetry Qmax &lt; 10ml/s and/or postvoid residual urine &gt; 100 ml ( urology preinclusion visit ) Previous know OAB Patients treat nonauthorized drug , Patients treat anticholinergic cholinesterase inhibitor within 12 month irradiation , Patients treat anticholinergic week follow irradiation Succinate Solifenacin treatment start , Patients treat botulinum toxin within 9 month screen , Patients treat alphablockers , 5alpha reductase inhibitor within 12 month precede irradiation , week follow irradiation Succinate Solifenacin treatment start , Contraindication Succinate Solifenacin Hypersensitivity allergy Solifenacin succinate antimuscarinic agent , Specific precaution use patient decompensated urinary tract obstruction risk urinary retention , vegetative neuropathy , long QT syndrome hypokaliemia , history long QT patient risk QT prolongation , obstructive gastrointestinal disorder . Patients treat oral biphosphonates , drug cause QT prolongation substrates affinity CYP3A4 isoenzyme verapamil Diltiazem , treat CYP3A4 inductor rifampicin , phenytoin , carbamazepine Galactose hereditary intolerance , lactase deficiency malabsorption syndrome glucose galactose . Patient enable follow study medical care family , social , geographical psychological reason . Participation another clinical study urinary toxicity and/or molecule could modify toxicity evolution .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>